Glenmark partners with Particle Sciences in Abraxane generic deal
India-based pharmaceutical company Glenmark has signed a wide-ranging drug agreement with Particle Sciences, a provider of drug development services.
The development, licensing and commercialisation agreement will see the companies develop and market a generic version of Celgene’s Abraxane (paclitaxel protein-bound particles for injectable suspension) product.
Glenmark has obtained global exclusive marketing and distribution rights to the product, while Particle Sciences will develop the product exclusively for Glenmark.
An Abbreviated New Drug Application is expected to be filed in 2019, kickstarting development in the US.
The drug is used to treat breast, lung and pancreatic cancer.
“The partnership is a significant development in Glenmark’s complex generics strategy and we are pleased to collaborate with Particle Sciences given their strong technical capabilities and understanding of particulate injection products,” said Robert Matsuk, president of North America and global API at Glenmark.
He added: “This is a challenging product to develop and we expect it to remain a limited competition opportunity.”
Abraxane reported sales of $967 million worldwide and $654 million in the US during 2015, according to Glenmark.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk